GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shandong Boan Biotechnology Co Ltd (HKSE:06955) » Definitions » EBIT

Shandong Boan Biotechnology Co (HKSE:06955) EBIT : HK$-115.2 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Shandong Boan Biotechnology Co EBIT?

Shandong Boan Biotechnology Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was HK$8.5 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-115.2 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shandong Boan Biotechnology Co's annualized ROC % for the quarter that ended in Dec. 2023 was -1.08%. Shandong Boan Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 2.33%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Shandong Boan Biotechnology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -2.29%.


Shandong Boan Biotechnology Co EBIT Historical Data

The historical data trend for Shandong Boan Biotechnology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Boan Biotechnology Co EBIT Chart

Shandong Boan Biotechnology Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EBIT
-271.13 -261.81 -355.50 -115.16

Shandong Boan Biotechnology Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBIT Get a 7-Day Free Trial -112.00 -171.93 -191.71 -123.62 8.45

Competitive Comparison of Shandong Boan Biotechnology Co's EBIT

For the Biotechnology subindustry, Shandong Boan Biotechnology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shandong Boan Biotechnology Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shandong Boan Biotechnology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shandong Boan Biotechnology Co's EV-to-EBIT falls into.



Shandong Boan Biotechnology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-115.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shandong Boan Biotechnology Co  (HKSE:06955) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shandong Boan Biotechnology Co's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=16.008 * ( 1 - 230.97% )/( (1731.129 + 2145.923)/ 2 )
=-20.9656776/1938.526
=-1.08 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2344.166 - 459.761 - ( 273.413 - max(0, 577.502 - 730.778+273.413))
=1731.129

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2541.271 - 330.095 - ( 220.779 - max(0, 714.619 - 779.872+220.779))
=2145.923

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Shandong Boan Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=16.908/( ( (726.571 + max(-101.05, 0)) + (721.757 + max(-38.23, 0)) )/ 2 )
=16.908/( ( 726.571 + 721.757 )/ 2 )
=16.908/724.164
=2.33 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(174.384 + 175.364 + 8.963) - (459.761 + 0 + -1.1368683772162E-13)
=-101.05

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(233.193 + 180.792 + 74.924) - (330.095 + 0 + 197.044)
=-38.23

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Shandong Boan Biotechnology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-115.164/5031.768
=-2.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shandong Boan Biotechnology Co EBIT Related Terms

Thank you for viewing the detailed overview of Shandong Boan Biotechnology Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Boan Biotechnology Co (HKSE:06955) Business Description

Traded in Other Exchanges
Address
No. 39 Keji Avenue, High-Tech Industrial Development Zone, Shandong Province, Yantai, CHN
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. The company is engaged in the development, manufacture, and commercialization of high-quality biologics in China and around the world. It focuses on areas such as oncology, metabolism, autoimmunity, and ophthalmology. Geographically company's revenue is generated from customers located in Mainland China.
Executives
Asiapharm Investments Ltd.
Ginkgo (ptc) Limited
Liu Dianbo
Luye Life Sciences Group Ltd
Luye Pharma Holdings Ltd.
Luye Pharma Hong Kong Limited
Luye Pharmaceutical International Co., Ltd.
Luye Pharmaceutical Investment Co., Ltd.
Nelumbo Investments Limited
Shorea Lbg
Luye Pharma Group Ltd.
Shan Dong Lv Ye Zhi Yao You Xian Gong Si
Yan Tai Lv Ye Yi Yao Kong Gu Ji Tuan You Xian Gong Si
Li Li 2201 Interest of corporation controlled by you

Shandong Boan Biotechnology Co (HKSE:06955) Headlines

No Headlines